How Animal Models of Leukaemias Have Already Benefited Patients

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2013 Mar 5

PMID 23453906

Citations 5

Authors

Julien Ablain

Rihab Nasr

Jun Zhu

Ali Bazarbachi

Valerie Lallemand-Breittenbach

Hugues de The

Affiliations

Soon will be listed here.

Abstract

The relative genetic simplicity of leukaemias, the development of which likely relies on a limited number of initiating events has made them ideal for disease modelling, particularly in the mouse. Animal models provide incomparable insights into the mechanisms of leukaemia development and allow exploration of the molecular pillars of disease maintenance, an aspect often biased in cell lines or ex vivo systems. Several of these models, which faithfully recapitulate the characteristics of the human disease, have been used for pre-clinical purposes and have been instrumental in predicting therapy response in patients. We plea for a wider use of genetically defined animal models in the design of clinical trials, with a particular focus on reassessment of existing cancer or non-cancer drugs, alone or in combination.

Citing Articles

Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Dozzo A, Galvin A, Shin J, Scalia S, ODriscoll C, Ryan K Drug Deliv Transl Res. 2022; 13(8):2110-2141.

PMID: 35930221 PMC: 10315355. DOI: 10.1007/s13346-022-01189-4.

In Vitro and In Vivo Modeling of Normal and Leukemic Bone Marrow Niches: Cellular Senescence Contribution to Leukemia Induction and Progression.

Salazar-Terreros M, Vernot J Int J Mol Sci. 2022; 23(13).

PMID: 35806354 PMC: 9266537. DOI: 10.3390/ijms23137350.

Murine Models of Acute Myeloid Leukaemia.

Almosailleakh M, Schwaller J Int J Mol Sci. 2019; 20(2).

PMID: 30669675 PMC: 6358780. DOI: 10.3390/ijms20020453.

Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice.

Gopalakrishnapillai A, Kolb E, Dhanan P, Bojja A, Mason R, Corao D Front Oncol. 2016; 6:162.

PMID: 27446808 PMC: 4921874. DOI: 10.3389/fonc.2016.00162.

How animal models of leukaemias have already benefited patients.

Ablain J, Nasr R, Zhu J, Bazarbachi A, Lallemand-Breittenbach V, de The H Mol Oncol. 2013; 7(2):224-31.

PMID: 23453906 PMC: 5528420. DOI: 10.1016/j.molonc.2013.01.006.

References

Bazarbachi A, El-Sabban M, Nasr R, Quignon F, Awaraji C, Kersual J . Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1998; 93(1):278-83. View

Tallman M, Altman J . How I treat acute promyelocytic leukemia. Blood. 2009; 114(25):5126-35. DOI: 10.1182/blood-2009-07-216457. View

Michor F, Iwasa Y, Nowak M . The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A. 2006; 103(40):14931-4. PMC: 1595453. DOI: 10.1073/pnas.0607006103. View

Shen Z, Shi Z, Fang J, Gu B, Li J, Zhu Y . All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101(15):5328-35. PMC: 397380. DOI: 10.1073/pnas.0400053101. View

Anderson K, Lutz C, van Delft F, Bateman C, Guo Y, Colman S . Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature. 2010; 469(7330):356-61. DOI: 10.1038/nature09650. View

Ablain J, Nasr R, Zhu J, Bazarbachi A, Lallemand-Breittenbach V, de The H . How animal models of leukaemias have already benefited patients. Mol Oncol. 2013; 7(2):224-31. PMC: 5528420. DOI: 10.1016/j.molonc.2013.01.006. View

Piazza F, Gurrieri C, Pandolfi P . The theory of APL. Oncogene. 2001; 20(49):7216-22. DOI: 10.1038/sj.onc.1204855. View

Ablain J, de The H . Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. 2011; 117(22):5795-802. DOI: 10.1182/blood-2011-02-329367. View

Kool J, Berns A . High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer. 2009; 9(6):389-99. DOI: 10.1038/nrc2647. View

10.

Rowley J, Golomb H, Dougherty C . 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet. 1977; 1(8010):549-50. DOI: 10.1016/s0140-6736(77)91415-5. View

11.

Haluska F, Croce C . Molecular mechanisms of chromosome translocation in human B- and T-cell neoplasia. Ann N Y Acad Sci. 1987; 511:196-206. DOI: 10.1111/j.1749-6632.1987.tb36248.x. View

12.

He L, Bhaumik M, Tribioli C, Rego E, Ivins S, Zelent A . Two critical hits for promyelocytic leukemia. Mol Cell. 2000; 6(5):1131-41. DOI: 10.1016/s1097-2765(00)00111-8. View

13.

Pear W, Miller J, Xu L, Pui J, Soffer B, Quackenbush R . Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998; 92(10):3780-92. View

14.

He L, Tribioli C, Rivi R, Peruzzi D, Pelicci P, Soares V . Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice. Proc Natl Acad Sci U S A. 1997; 94(10):5302-7. PMC: 24673. DOI: 10.1073/pnas.94.10.5302. View

15.

Figueroa M, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos P . DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17(1):13-27. PMC: 3008568. DOI: 10.1016/j.ccr.2009.11.020. View

16.

Akagi T, Shih L, Kato M, Kawamata N, Yamamoto G, Sanada M . Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood. 2008; 113(8):1741-8. PMC: 2647673. DOI: 10.1182/blood-2007-12-130260. View

17.

Kchour G, Tarhini M, Kooshyar M, El Hajj H, Wattel E, Mahmoudi M . Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood. 2009; 113(26):6528-32. DOI: 10.1182/blood-2009-03-211821. View

18.

Jing Y, Wang L, Xia L, Chen G, Chen Z, Miller W . Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood. 2001; 97(1):264-9. DOI: 10.1182/blood.v97.1.264. View

19.

Zhu J, Nasr R, Peres L, Riaucoux-Lormiere F, Honore N, Berthier C . RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell. 2007; 12(1):23-35. DOI: 10.1016/j.ccr.2007.06.004. View

20.

El Hajj H, El-Sabban M, Hasegawa H, Zaatari G, Ablain J, Saab S . Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010; 207(13):2785-92. PMC: 3005222. DOI: 10.1084/jem.20101095. View